ReviewSchizophrenia bulletin2010
Fibroblast growth factors in schizophrenia.
Review in Schizophrenia bulletin, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 77 citations in OpenAlex.
- Increased inflammatory cytokines in the temporal cortex in autism spectrum disorder.Brain, behavior, & immunity - health · 2026Article
- Article
- Differential brain neuroimmune profiles and altered immune balance in autism spectrum disorder compared with psychotic disorder and neurotypical controls.Research square · 2026Article
- Dysregulation of the BRD2-FGF17 Signal Pathway Induces Abnormal Forebrain Development Associated with Schizophrenia.Neuroscience bulletin · 2026Article
- Genetic estimates and genome-wide association studies of antibody response in Tanzanian dairy cattle.Frontiers in genetics · 2025Article
- Single-cell genomics and regulatory networks for 388 human brains.Science (New York, N.Y.) · 2024Article
- Single-cell genomics and regulatory networks for 388 human brains.bioRxiv : the preprint server for biology · 2024Article
- Transcriptome analysis to explore the mechanism of downregulated TNIK influencing the effect of risperidone.Frontiers in pharmacology · 2024Article
- DeepGAMI: deep biologically guided auxiliary learning for multimodal integration and imputation to improve genotype-phenotype prediction.Genome medicine · 2023Article
- Maternal FGF2 levels associated with child anxiety and depression symptoms through child FGF2 levels.Journal of affective disorders · 2023Article
- The FGF/FGFR system in the microglial neuroinflammation with Borrelia burgdorferi: likely intersectionality with other neurological conditions.Journal of neuroinflammation · 2023Article
- Review
- Fibroblast Growth Factor 9 as a Potential Biomarker for Schizophrenia.Frontiers in psychiatry · 2022Article
- Leukocyte methylomic imprints of exposure to the genocide against the Tutsi in Rwanda: a pilot epigenome-wide analysis.Epigenomics · 2022Article
- Molecular and Clinical Significance of Fibroblast Growth Factor 2 in Development and Regeneration of the Auditory System.Frontiers in molecular neuroscience · 2021Review
- Growth Factors and Alcohol Use Disorder.Cold Spring Harbor perspectives in medicine · 2020Review
- Dysregulation of Fibroblast Growth Factor 10 in the Peripheral Blood of Patients with Schizophrenia.Journal of molecular neuroscience : MN · 2019Article
- Longitudinal investigation of DNA methylation changes preceding adolescent psychotic experiences.Translational psychiatry · 2019Article
- Primary Cilia-An Underexplored Topic in Major Mental Illness.Frontiers in psychiatry · 2019Review
- Fibroblast Growth Factors in Depression.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large association study by O'Donovan et al recently suggested that genetic variation in fibroblast growth factor receptor (FGFR) 2 increases the risk for developing schizophrenia. Fibroblast growth factors (FGFs) are part of the family of glial growth factors; they control the growth and patterning of specific brain structures and regulate the maintenance and repair of neuronal tissues. In addition, a direct interaction was recently found between FGFRs and adenosine A(2A) receptors, leading to corticostriatal plasticity and antagonizing the signaling pathway of dopamine D(2) receptors. These findings make FGFs plausible candidate genes for schizophrenia. Here, we review the role of FGFs in schizophrenia and combine evidence from studies on variations in FGF genes, RNA expression, protein levels, and FGF administration, as well as the effects of medication and environmental risk factors for schizophrenia. These data suggest that changes in the FGF system contribute to schizophrenia and possibly to a wider range of psychiatric disorders. The role of FGFs in schizophrenia and related disorders needs to be studied in more detail.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.